Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016826
Chunk: 18

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 18
---
 The selling shareholders may sell some, all or none of their Ordinary Shares represented
by Depositary Shares. We do not know how long the selling shareholders will hold the warrants, whether any will exercise the warrants,
and upon such exercise, how long such selling shareholders will hold the Ordinary Shares represented by Depositary Shares before selling
them, and we currently have no agreements, arrangements or understandings with the selling shareholders regarding the sale of any of
the shares.

The table below lists
the selling shareholders and other information regarding the beneficial ownership of the Ordinary Shares represented by Depositary Shares
by each of the selling shareholders. The second column lists the number of Ordinary Shares represented by Depositary Shares beneficially
owned by each selling shareholder, based on its ownership of Depositary Shares and warrants to purchase Depositary Shares, as of November
1, 2025, assuming exercise of the warrants held by the selling shareholders on that date, without regard to any limitations on conversions
or exercises. The third column lists the maximum number of Ordinary Shares represented by Depositary Shares being offered in this prospectus
by the selling shareholders. The fourth column lists the amount of Ordinary Shares represented by Depositary Shares owned after the offering,
assuming the sale of all of the Ordinary Shares represented by Depositary Shares offered by the selling shareholders pursuant to this
prospectus, and without regard to any limitations on conversions or exercises.

In accordance with the
terms of a registration rights agreement with the selling shareholders, this prospectus generally covers the resale of the sum of (i)
the number of Ordinary Shares issued to the selling shareholders in the December 2023 Private Placement and the number of Ordinary Shares
issued to the selling shareholders upon the exercise of the warrants issued in the December 2023 Private Placement and (ii) the maximum
number of Ordinary Shares upon exercise of the related warrants, determined as if the outstanding warrants were exercised in full as
of the trading day immediately preceding the date this registration statement was initially filed with the SEC, each as of the trading
day immediately preceding the applicable date of determination and all subject to adjustment as provided in the registration right agreement,
without regard to any limitations on the exercise of the warrants.

Under the terms of the warrants,
a selling shareholder may not exercise the warrants to the extent such exercise would cause such selling shareholder, together with its
affiliates and attribution parties, to beneficially own a number of Ordinary Shares which would exceed 4.99% or 9.99%, as applicable,
of our then outstanding Ordinary